Literature DB >> 20497168

Which benefits of research participation count as 'direct'?

Alexander Friedman, Emily Robbins, David Wendler.   

Abstract

It is widely held that individuals who are unable to provide informed consent should be enrolled in clinical research only when the risks are low, or the research offers them the prospect of direct benefit. There is now a rich literature on when the risks of clinical research are low enough to enroll individuals who cannot consent. Much less attention has focused on which benefits of research participation count as 'direct', and the few existing accounts disagree over how this crucial concept should be defined. This disagreement raises concern over whether those who cannot consent, including children and adults with severe dementia, are being adequately protected. The present paper attempts to address this concern by considering first what additional protections are needed for these vulnerable individuals. This analysis suggests that the extant definitions of direct benefits either provide insufficient protection for research subjects or pose excessive obstacles to appropriate research. This analysis also points to a modified definition of direct benefits with the potential to avoid these two extremes, protecting individuals who cannot consent without blocking appropriate research. Published 2010. This article is a US Government work and is in the public domain in the USA.

Entities:  

Mesh:

Year:  2010        PMID: 20497168      PMCID: PMC2945615          DOI: 10.1111/j.1467-8519.2010.01825.x

Source DB:  PubMed          Journal:  Bioethics        ISSN: 0269-9702            Impact factor:   1.898


  9 in total

1.  Is payment a benefit?

Authors:  Alan Wertheimer
Journal:  Bioethics       Date:  2011-07-04       Impact factor: 1.898

2.  The Role of Inclusion Benefits in Ethics Committee Assessment of Research Studies.

Authors:  Stuart Rennie; Suzanne Day; Allison Mathews; Adam Gilbertson; Winfred K Luseno; Joseph D Tucker; Gail E Henderson
Journal:  Ethics Hum Res       Date:  2019-05

3.  How legislation on decisional capacity can negatively affect the feasibility of clinical trials in patients with dementia.

Authors:  Francesca Galeotti; Nicola Vanacore; Sabina Gainotti; Fabio Izzicupo; Francesca Menniti-Ippolito; Carlo Petrini; Flavia Chiarotti; Rabih Chattat; Roberto Raschetti
Journal:  Drugs Aging       Date:  2012-08-01       Impact factor: 3.923

4.  Standards of evidence for institutional review board decision-making.

Authors:  David B Resnik
Journal:  Account Res       Date:  2020-12-08       Impact factor: 3.057

5.  Ethics of treatment interruption trials in HIV cure research: addressing the conundrum of risk/benefit assessment.

Authors:  Gail E Henderson; Holly L Peay; Eugene Kroon; Rosemary Jean Cadigan; Karen Meagher; Thidarat Jupimai; Adam Gilbertson; Jill Fisher; Nuchanart Q Ormsby; Nitiya Chomchey; Nittaya Phanuphak; Jintanat Ananworanich; Stuart Rennie
Journal:  J Med Ethics       Date:  2017-11-10       Impact factor: 2.903

6.  Motivators and barriers to research participation for individuals with cerebral palsy and their families.

Authors:  Kristina M Zvolanek; Vatsala Goyal; Alexandra Hruby; Carson Ingo; Theresa Sukal-Moulton
Journal:  PLoS One       Date:  2022-01-26       Impact factor: 3.240

7.  Challenging research on human subjects: justice and uncompensated harms.

Authors:  Stephen Napier
Journal:  Theor Med Bioeth       Date:  2013-02

8.  Non-beneficial pediatric research: individual and social interests.

Authors:  Jan Piasecki; Marcin Waligora; Vilius Dranseika
Journal:  Med Health Care Philos       Date:  2015-02

9.  Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.

Authors:  Nir Eyal
Journal:  Ethics Hum Res       Date:  2020-05-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.